Tokyo, Feb. 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060549) titled 'Study on ways to promote understanding of guideline-based cancer screening' on Feb. 3.

Study Type: Interventional

Study Design: Basic Design - Parallel Randomization - Randomized Blinding - Double blind -all involved are blinded Control - Placebo

Primary Sponsor: Institute - Tokai University

Condition: Condition - Stomach cancer, colon cancer, lung cancer, cervical cancer, breast cancer Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To examine what approaches are appropriate to advance the understanding of the benefits-disadvantages of cancer screening for ordinary employees. Basic objectives2 - Others

Intervention: Interventions/Control_1 - A science-based explanatory video detailing the potential harms of screening outside guideline recommendations, such as screening at a young age, overly frequent screening, and overdiagnosis Interventions/Control_2 - A narrative-style video depicting a realistic personal story of an individual adversely affected by inappropriate screening

Eligibility: Age-lower limit - 30 years-old = Gender - Male and Female Key inclusion criteria - Individuals registered as panel members with a survey company (Rakuten Insight, Inc.) Employed persons aged between 30 and 60 years Those who provided informed consent to participate in the study Key exclusion criteria - Individuals with a history of gastric, colorectal, lung, cervical, or breast cancer Individuals who have undergone cancer screenings offered by local governments within the past three years Target Size - 1200

Recruitment Status: Recruitment status - Completed Date of protocol fixation - 2025 Year 02 Month 01 Day Date of IRB - 2025 Year 02 Month 10 Day Anticipated trial start date - 2025 Year 06 Month 01 Day Last follow-up date - 2025 Year 06 Month 15 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066119

Disclaimer: Curated by HT Syndication.